Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1, Peg-Asparaginase, and Chidamide in Stage I/II ENKTL
NCT04414969Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Jun 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Hunan Cancer Hospital. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on NCT04414969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414969.